Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170105 | 0.81 | CYP1A2 (0.50) | SCN8ACYP1A2PTGER4MEN1KMT2A | |
| SCHEMBL844215 | 0.81 | ESR2 (0.46) | SCN8ACYP1A2PTGER4KMT2AESR2 | |
| SCHEMBL25247023 | 0.80 | SCN8A (0.49) | SCN8ACYP1A2PTGER4SLC9A1GRM2 | |
| Hydrochloric Acid SCHEMBL845090 | 0.79 | ESR2 (0.45) | SCN8ACYP1A2PTGER4KMT2AESR2 | |
| SCHEMBL845240 | 0.79 | ESR2 (0.49) | SCN8ACYP1A2PTGER4MEN1KMT2A | |
| SCHEMBL25153638 | 0.79 | MPO (0.45) | CYP1A2PTGER4MEN1KMT2ASLC9A1 | |
| SCHEMBL23229321 | 0.76 | ATM (0.58) | MEN1KMT2AALDH1A1ESR2ESR1 | |
| SCHEMBL18096451 | 0.76 | PTGER4 (0.47) | SCN8ACYP1A2PTGER4MEN1KMT2A | |
| SCHEMBL4494497 | 0.74 | ALDH1A1 (0.53) | SCN8ACYP1A2PTGER4MEN1KMT2A | |
| SCHEMBL11394219 | 0.73 | MPO (0.42) | SCN8ACYP1A2PTGER4SLC9A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8519186-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype 1 (VR1) receptors | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2012779-B1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LAB (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2011-02-17 | — | — | US | disclosed |
| US-7847104-B2 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors | ABBOTT LABORATORIES (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2012779-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | Abbott Laboratories (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121339-A2 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | ABBVIE INC. | 2007-10-18 | — | — | US | disclosed |
| US-4264618-A | Basic thio-indazoles | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1981-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244178-A1 | Process for the Preparation of Indazolyl Ureas that Inhibit Vanilloid Subtype1 (VR1) Receptors | UTS2R, VIPR1, VRK1 | SCN8A 437/4885CYP1A2 805/4885PTGER4 877/4885 |
| US-20110040102-A1 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS | UTS2R, VIPR1, VRK1 | SCN8A 410/4885CYP1A2 822/4885PTGER4 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.